What is Ginkgo Bioworks Holdings Inc (DNA) Stock Return on Shareholders’ Capital?

With 27.43 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.3 shares. The 52-week range on DNA shows that it touched its highest point at $2.55 and its lowest point at $1.12 during that stretch. It currently has a 1-year price target of $3.02. Beta for the stock currently stands at 1.36.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Price Performance and Earnings:

Three-month performance dropped to -5.37% while six-month performance fell -19.43%. The stock lost -22.95% in the past year, while it has lost -16.57% so far this year. A look at the trailing 12-month EPS for DNA yields -0.45 with Next year EPS estimates of -0.30. For the next quarter, that number is -0.10. This implies an EPS growth rate of 64.80% for this year and 31.82% for next year.

Float and Shares Shorts:

At present, 1.34 billion DNA shares are outstanding with a float of 1.32 billion shares on hand for trading. On Jan 31, 2024, short shares totaled 236.91 million, which was 11.18% higher than short shares on Dec 29, 2023. In addition to Dr. Jason Kelly as the firm’s Founder, CEO & Director, Dr. Reshma P. Shetty serves as its Founder, President, COO & Director.


Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DNA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With DNA analysts setting a high price target of $7.00 and a low target of $1.10, the average target price over the next 12 months is $3.02. Based on these targets, DNA could surge 396.45% to reach the target high and fall by -21.99% to reach the target low. Reaching the average price target will result in a growth of 114.18% from current levels.

Summary of Insider Activity:

Insiders traded DNA stock several times over the past three months with 0 Buys and 6 Sells. In these transactions, 0 shares were bought while 350,600 shares were sold. The number of buy transactions has increased to 36 while that of sell transactions has risen to 226 over the past year. The total number of shares bought during that period was 1,546,736 while 13,096,320 shares were sold.